Results 221 to 230 of about 246,372 (396)

Dupilumab and Systemic Hematologic Malignancies: Case Series and Literature Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 15%–20% of children and 3%–10% of adults. An increased risk of systemic lymphomas – but not leukemias – has been reported in patients with AD. Dupilumab, a monoclonal IgG4 antibody targeting IL‐4 and IL‐13 signaling, is approved for moderate‐to‐severe AD and is ...
Nello Tommasino   +3 more
wiley   +1 more source

Relationship of low hematocrit level and physical training

open access: bronze, 1983
庄司 下村   +8 more
openalex   +2 more sources

Predicting Adverse Events in Blunt Chest Trauma: A Novel Nomogram Integrating Vitals, Hemogram, and Comorbidities

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Blunt chest trauma (BCT) is common and frequently associated with adverse complications. Beyond merely impeding regular respiration, adverse events (AEs) such as hemothorax or pneumothorax can hinder the patient's recovery. Herein, we aim to validate potential predictive factors for AEs among adults with BCT who were admitted concurrently ...
Chang‐Lun Huang   +6 more
wiley   +1 more source

Routine Hematocrit After Elective Gynecologic Surgery [PDF]

open access: bronze, 2000
Neeraj Kohli   +4 more
openalex   +1 more source

A single intra‐articular stromal vascular fraction with platelet‐rich plasma injection yields superior clinical outcomes than a hyaluronic acid injection in patients with knee osteoarthritis: A prospective comparative study

open access: yesKnee Surgery, Sports Traumatology, Arthroscopy, EarlyView.
Abstract Purpose The present study aimed to compare the efficacy and safety of a combined injection of stromal vascular fraction (SVF) and platelet rich plasma (PRP) versus a high molecular weight (HMW) hyaluronic acid (HA) injection in patients with knee osteoarthritis (KOA).
Trifon Totlis   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy